Лечащий Врач (Feb 2022)

Possibilities of modern probiotic therapy in the treatment of patients with post-infectious irritable bowel syndrome

  • V. A. Akhmedov,
  • O. V. Gaus

DOI
https://doi.org/10.51793/os.2022.25.2.005
Journal volume & issue
Vol. 0, no. 2
pp. 32 – 35

Abstract

Read online

Irritable bowel syndrome is a chronic disease of the gastrointestinal tract, with such characteristic symptoms as pain and discomfort in the abdomen in the absence of an organic pathological process, the frequency of which in recent years has begun to increase due to post-COVID-19 postinfectious irritable bowel syndrome. Purpose of the study was to evaluate the effectiveness of including the probiological drug in the therapy of patients with post-infectious irritable bowel syndrome after a previous COVID-19 infection. We examined 70 patients with postinfectious irritable bowel syndrome that developed after a previous infection with COVID-19. The patients were divided into 2 groups. The main group consisted of 35 people who were treated with irritable bowel syndrome based on the latest recommendations of the Russian Gastroenterological Association, including antispasmodics, antidiarrheals. Additionally, the patients of the main group were included in the combined probiotic enteric capsules for 2 weeks at a dose of 3 capsules per day. In patients of the main group, whom included the probiotic in therapy, there was a more pronounced relief from the clinical manifestations of the disease with an overall assessment of the effectiveness of treatment of 82,7% in the main group and 56,9% in the comparison group. When assessing the indicators in points according to the IBS-SSS test and the IBS-QOL scale, both groups of patients showed statistically significant improvements in indicators (p < 0.001), however, the best indicators of intestinal symptoms and quality of life were in the main group. The combined probiotic is an interesting combination in the treatment of patients with post-COVID-19 postinfectious irritable bowel syndrome, contributing to a more pronounced regression of the clinical manifestations of the disease and improving the quality of life of patients.

Keywords